Top of this page
Skip navigation, go straight to the content

This section is intended for media and financial analysts
Newsroom Press Releases

UCB supports new epilepsy patient centre in Beijing and partners with Chinese association to open more

· UCB part of Belgian trade mission to China

· HRH Princess Mathilde of Belgium inaugurates new patient centre

· Signing of memorandum of understanding with CAAE in presence of HRH Prince Philippe of Belgium

Luc Vermeesch, Head International Major Markets

Luc Vermeesch, Head of UCB’s International Major Markets commented: “Opening this first awareness centre today is an important milestone in the UCB-CAAE partnership which will continue to blossom in the future. Our passion is to improve the lives of epilepsy patients all over the world – and this of course includes people who live with epilepsy here in China, as well as their families”.
Epilepsy is the most common serious neurological disorder and is one of the world's most prevalent non-communicable diseases. In China, epilepsy constitutes a significant health challenge that affects nine million people with around 400,000 new cases diagnosed every year.

For further information, please contact:

In China during the mission: Didier Malherbe, VP Public Affairs, +32 475 86 79 91

For other inquiries: France Nivelle, VP Global Communications: +32 475 494 001

About UCB
UCB, Brussels, Belgium ( is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. UCB employs more than 8500 people in about 40 countries. UCB entered China in 1996 and currently employs about 750 people all across China.

Stay up-to-date on the latest news and information from UCB